Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05128383 · ClinicalTrials.gov registry record · Phase 2
Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT05128383 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT05128383, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The study investigates the efficacy and safety of dupilumab in the treatment of keloids
Interventions
- DRUG Dupilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-01-13 |
| Est. Completion | 2025-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05128383
The ClinicalTrials.gov registry entry for NCT05128383 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dupilumab is the first listed.
NCT05128383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05128383 about?
NCT05128383 is a clinical study titled "Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids". The study investigates the efficacy and safety of dupilumab in the treatment of keloids
What is the current status of trial NCT05128383?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-01-13. Estimated completion is 2025-06-10.
What interventions are being tested in trial NCT05128383?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT05128383?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.